Publications and Research

• Alfano RW, Leppla SH, Liu S, Bugge TH, Duesbery NS, Frankel AE. Potent inhibition of tumor angiogenesis by the matrix metalloproteinase-activated anthrax lethal toxin: implications for broad anti-tumor efficacy.  Cell Cycle 7[6], 745-749. 2008.
• Ding Y, Boguslawski EA, Berghuis BD, Young JJ, Zhang ZF, Hardy K, Furge K, Kort E, Frankel AE, Hay RV, Resau JH, Duesbery NS. Mitogen-activated protein kinase kinase signaling promotes growth and vascularization of fibrosarcoma.  Molecular Cancer Therapeutics 7[3], 648-658. 2008.
• Frankel AE, Liu JS, Rizzieri D, Hogge D. Phase I clinical study of diphtheria toxin-interleukin 3 fusion protein in patients with acute myeloid leukemia and myelodysplasia.  Leukemia and Lymphoma 49[3], 543-553. 2008.
• Horita H, Frankel AE, Thorburn A. Acute-myeloid-leukemia-targeted toxins kill tumor cells by cell-type-specific mechanisms and synergize with TRAIL to allow manipulation of the extent and mechanism of tumor cell death.  Leukemia 22[3], 652-655. 2008.
• Liu S, Wang H, Currie BM, Molinolo A, Leung HJ, Moayeri M, Basile JR, Alfano RW, Gutkind JS, Frankel AE, Bugge TH, Leppla SH. Matrix metalloproteinase-activated anthrax lethal toxin demonstrates high potency in targeting tumor vasculature.  Journal of Biological Chemistry 283[1], 529-540. 2008.
• Rouleau C, Menon K, Boutin P, Guyre C, Yoshida H, Kataoka S, Perricone M, Shankara S, Frankel AE, Duesbery NS, Woude GV, Biemann HP, Teicher BA. The systemic administration of lethal toxin achieves a growth delay of human melanoma and neuroblastoma xenografts: Assessment of receptor contribution.  International Journal of Oncology 32[4], 739-748. 2008.
• Read more publications.